InsidersTradesSigma
申报总数
公司
▲ 买入（1 笔）
▼ 卖出（2 笔）
内部人交易记录
董事已披露买入
1
已披露卖出
2
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
Discover the complete record of transactions filed by Kozin Marc d, 董事. Officer active across 6 companies, notably Dicerna Pharmaceuticals Inc. Cumulatively, 18 filings have been logged. Breakdown: 1 buy · 2 sells. Total volume traded: €1.9m. Activity tracked since 9 June 2021. The latest transaction was filed on 25 August 2026 (Cession). Regulator: SEC (Form 4). The full history is free.
Companies and markets linked to Kozin Marc d
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报18 总计
3,650 股@ US$303.97Common Stock, $.01 Par ValueSEC:0002084956-26-000064:0
3,350 股@ US$305.07Common Stock, $.01 Par ValueSEC:0002084956-26-000064:1
625 股0Common Stock, $.01 Par ValueSEC:0001062993-25-011131:0
1,500 股0Common Stock, $.01 Par ValueSEC:0001062993-24-017375:0
230 股0Common Stock, $.01 Par ValueSEC:0001062993-24-012212:0
298 股0Common Stock, $.01 Par ValueSEC:0001062993-23-013202:0
1,000 股0Common Stock, $.01 Par ValueSEC:0001062993-23-006525:0
647 股0Common Stock, $.01 Par ValueSEC:0001240679-22-000039:0
6,333 股@ US$38.2577.9% 占其流量Common StockSEC:0001399529-21-000202:0
36,000 股0Common StockSEC:0000899243-21-035571:0
3,000 股@ US$23.66222.1% 占其流量Common StockSEC:0001399529-21-000144:0
标准退出：2021年11月8日 (T+90)
610 股0Common Stock, $.01 Par ValueSEC:0001240679-21-000044:0
3,333 股Common StockSEC:0001399529-21-000109:0
131,305 股Common StockSEC:0000908662-16-000435:0
25,000 股Common StockSEC:0000908662-16-000395:0
66,667 股Common StockSEC:0000908662-16-000395:1
16,667 股Common StockSEC:0000908662-16-000395:2
991 股Common StockSEC:0001179110-16-017279:0
18 条申报中的 18 条
About Kozin Marc d
KOZIN MARC D is an Administrateur. He has 16 filings, with buys of EUR 60551 and sells of EUR 213801 across the sampled recent filings, from 2016-01-05 to 2025-06-06, and the modal transaction nature is Attribution. He is listed at UFP Technologies INC, DYAX CORP, Dicerna Pharmaceuticals Inc, Isleworth Healthcare Acquisition Corp., and OvaScience, Inc.
